Is TB-500 actually better than LL-37

Is TB-500 actually better than LL-37? Wrong question, and I'll tell you why in a second. Short answer: TB-500 wins on tissue repair, LL-37 wins on stubborn infections, and asking which peptide is flat out "better" is like asking whether a plumber beats an electrician. Depends entirely what's broken in your house.

I get this question in my inbox constantly, usually from someone who read one Reddit thread that name-dropped both peptides in the same breath and assumed they're rivals. They are NOT rivals. They don't even play the same sport. TB-500 is a systemic repair coordinator. LL-37 is your body's own antibiotic. Comparing them head to head is like comparing a mechanic to a locksmith and asking which one you should hire. Depends what's broken.

But you asked, so let's actually do the comparison honestly, evidence quality and all.

What Each One Actually Does

TB-500 is a synthetic fragment of thymosin beta-4, a protein your cells already use to manage their internal scaffolding. The core mechanism is actin sequestration: TB-500 grabs the building blocks your cells need to physically crawl toward damaged tissue, and releases them on demand. No crawling, no repair. That's the whole game underneath everything else it does, angiogenesis, less scarring, calmer inflammation. I go deep on the full mechanism over on the TB-500 page if you want the whole map.

LL-37 does something TOTALLY different. It's a 37-amino-acid piece of your own cathelicidin defense system, the stuff your neutrophils release the second they smell an invader. It punches holes in bacterial membranes, cracks open the slimy biofilm colonies that let chronic infections hide from antibiotics, and revs up your immune cells. NOTHING to do with tissue repair. EVERYTHING to do with killing stuff that shouldn't be living in you. Full breakdown on the LL-37 page.

Here's the thing that trips people up: because both are peptides, because both show up in the same Discord servers, folks assume they're interchangeable tools for "healing." They are not. You wouldn't hire an electrician to fix a leaky faucet just because he's handy around the house.

The Evidence: Who's Actually Been Tested on Humans

This is where TB-500 pulls ahead, and it's not close.

TB-500's animal record is deep and mechanistically coherent. Wound healing accelerates in diabetic and aged animals, including burns. Cardiac studies show reduced infarct size and preserved heart function after a heart attack in animal models. There's even a 2025 human trial in actual heart attack patients using the pharmaceutical-grade version, and while the overall result missed statistical significance, the subgroup dosed early showed REAL infarct reduction. Not a slam dunk. Still a hell of a lot more than LL-37 has.

I'll be honest, I lean toward TB-500 when someone's rehabbing an injury, and toward LL-37 when the problem is something their body can't seem to kill on its own.

LL-37? ZERO completed human trials. For anything. The in vitro antimicrobial and anti-biofilm data is real and solid, LL-37 genuinely disrupts bacterial membranes and cracks open the biofilm colonies that make chronic Lyme and chronic UTIs so miserable to treat. But every bit of that evidence stops at the petri dish. Nobody has run this in humans yet. Here's what we have instead: decades of clinical use in the chronic-infection community and a mechanism that holds up under a microscope.

Yup. It's true. Neither one has a clean, dose-finding human trial behind it. But TB-500 at least has clinical-grade cousins that made it into real patients with real outcomes measured. LL-37 hasn't gotten that far yet.

Cost, Side Effects, and Who Actually Needs Which One

Before you pick a lane here, house foundations first: neither peptide fixes a diet that's garbage, sleep that's wrecked, or stress that never lets up. You cannot decorate a house with no foundation, and TB-500 or LL-37 layered onto a foundation-free life is just an expensive shrug.

Now, assuming your foundation's solid and you're choosing based on the actual problem you have:

TB-500 is for systemic recovery. Torn tendon, post-surgical repair, that nagging soft-tissue issue that never fully heals. Real-world dosing runs two flavors: a daily 500 mcg convention, or the more common loading approach of 2 to 5 mg twice weekly for four to six weeks, then dropping to a lower maintenance dose. Side effects are mild, injection-site irritation mostly, sometimes a flu-like first week that resolves on its own.

LL-37 is for infection your body can't clear on its own, chronic Lyme, stubborn UTIs, sinus infections that outlast every antibiotic course thrown at them. Community dosing runs 100 to 300 mcg a day. Side effects run a little heavier than TB-500's: mild injection-site stuff, occasional flu-like symptoms, and one RED FLAG worth knowing about, LL-37 has a documented role as an autoantigen in psoriasis and lupus. If you've got an active autoimmune condition in that family, this is NOT your peptide.

Now the part my lawyer makes me say, and honestly he's right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Cost-wise, TB-500 runs about $59 for a 10 mg vial through Alyve, code OHM-15 knocks 15% off and buying three vials in one order gets you over 30% off retail. LL-37 isn't in Alyve's catalog, US Pure Peptides carries it, code OHM20 for 20% off. And since I just mentioned vendors and discount codes, here's the straight version: Heads up, OHM has an affiliate relationship with the vendors linked here, so we earn a commission if you buy through one of these links. It costs you nothing extra and it does not change which peptide the evidence supports.

So which one's "better"? Neither. That's not a cop-out, that's the honest answer. TB-500 for repair, LL-37 for infection your immune system can't handle solo. Pick based on what's actually broken.

Thanks for reading! In health, Rick Gold